Vaster

Quick links to important sections

Vaster

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vaster

Property Description
Active ingredient Simvastatin
Form Oral tablet (Film-coated)
Pharmacological class HMG-CoA reductase inhibitor (Statin)
Common use Systemic lipid modification
Origin Synthetic (Prodrug)

What Type of Medicine is Vaster and What is Its Composition?

Vaster is a prescription-only medicine containing the active substance Simvastatin, which is classified within the pharmaceutical class of HMG-CoA reductase inhibitors, widely known as statins. This medicine is manufactured for oral administration as a single-component tablet, composed of Simvastatin and necessary solid pharmaceutical excipients. Simvastatin is a synthetic compound initially classified as an inactive prodrug that requires metabolic activation in the body to exert its effects.

The definitive characteristic of Vaster is its function as a statin, which works by competitively blocking the key enzyme in the liver's mevalonate pathway. This mechanism targets the endogenous synthesis of lipids, providing a direct and clinically recognized method for managing systemic lipid levels.

What is the General Purpose of Vaster (Simvastatin)?

The fundamental purpose of Vaster is to serve as an antihyperlipidemic agent, providing systemic and long-term management of elevated fat levels in the blood. By inhibiting cholesterol synthesis, the medication primarily acts to modify the patient's lipid profile, resulting in a significant reduction of Low-Density Lipoprotein cholesterol (LDL-C), often referred to as "bad cholesterol."

This sustained action means the medication is systematically utilized to address conditions such as severe hypercholesterolemia and generalized dyslipidemia. Through its controlled mechanism, Vaster helps support a stable, healthier cardiovascular environment for individuals with persistently elevated cholesterol levels.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Vaster?

Possible Side Effects and Safety Information

The safety profile of Vaster (Simvastatin) is defined by officially documented adverse reactions classified by frequency and by the body system affected, according to regulatory standards such as the EMA and FDA.

Classification of Adverse Reactions

Adverse effects are categorized based on their incidence rate reported in clinical data and post-marketing surveillance:

  • Common (ge 1/100 to <1/10): Reactions frequently listed include headache, constipation, abdominal pain, flatulence, nausea, and upper respiratory infection.
  • Uncommon (ge 1/1,000 to <1/100): These include myalgia (muscle pain), asthenia (weakness), and skin reactions like rash or pruritus.
  • Rare (ge 1/10,000 to <1/1,000): Rare but more serious effects involve the musculoskeletal system (myopathy, rhabdomyolysis) and the hepato-biliary system (hepatitis, jaundice, and pancreatitis).

Systemic and Serious Concerns

The most clinically significant adverse reactions officially documented are Myopathy and Rhabdomyolysis, which are explicitly noted in regulatory documents as dose-dependent. The potential for Hepatic Failure (fatal and non-fatal) is also a rare but serious adverse reaction. The highest approved dose is generally restricted to patients with chronic exposure without muscle toxicity.

Population-Specific Safety Statements

Official regulatory texts define clear constraints for certain groups. Vaster is contraindicated for use in individuals with active liver disease or unexplained persistent elevations of liver enzymes. Use is also contraindicated during pregnancy and lactation due to the potential for fetal harm.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented profile for Vaster (Simvastatin) overdose is primarily focused on the potential for severe systemic toxicities. Overdose is characterized by symptoms that are extensions of severe adverse reactions, especially those affecting muscle and liver function.

Documented Overdose Manifestations

The manifestations requiring immediate attention include signs of muscle injury, known as myopathy, which may present as unexplained muscle pain, tenderness, or weakness. A severe outcome of this toxicity is rhabdomyolysis, a breakdown of muscle tissue often indicated by dark-colored urine and a risk of subsequent acute renal failure. Symptoms of hepatic involvement, such as jaundice (yellowing of the skin or eyes) or unusual fatigue, are also officially documented.

Required Emergency Action

Regulatory authorities mandate that individuals seek emergency medical attention or call the Poison Help line immediately upon suspected overdose or the manifestation of severe symptoms. The official regulatory text confirms that no specific antidote is known for Vaster overdose. Therefore, management is confined to symptomatic and supportive treatment, including the immediate discontinuation of the medication. Monitoring of Creatine Kinase (CK) levels and Liver Enzyme tests is required to assess the severity of systemic injury.

Therapeutic Uses of Vaster

Quick Facts About Vaster

  • Relief of Pain: May be used in the management of mild to moderate pain.
  • Reduction of Discomfort: Thought to address physical discomfort associated with various conditions.

What Vaster treats: main uses and benefits

Vaster is a therapeutic agent used in the appropriate management of certain health conditions. Its primary role involves the temporary relief of mild to moderate pain. This includes symptom management for common ailments like tension headaches and general muscle discomfort. Individuals considering this treatment should discuss their specific needs with a healthcare provider.

Vaster may assist in reducing the physical symptoms of inflammation. By addressing these symptoms, it supports the patient's general well-being and helps in maintaining day-to-day comfort. The clinical context for its use focuses on providing symptomatic support rather than treating the underlying disease process. For comprehensive guidance on the approved uses of medications, patients should consult resources from health authorities.

Treatment with Vaster should be part of an overall care plan determined by a qualified health professional, with potential benefits and known safety information fully discussed before initiation.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vaster?

Eligibility for Vaster is strictly defined in regulatory documents based on a patient's medical status and age. The medicine is intended only for individuals who do not possess specific health conditions that make its use unsafe.

Population Eligibility Status Official Constraint
Contraindicated (Must not use) Individuals with a documented hypersensitivity or allergic reaction to the active substance or any non-active ingredients are formally prohibited from use.
Not Recommended (Avoid use) Use is officially not recommended in patients who have severe hepatic impairment (severe liver disease).
Restricted (Requires special consideration) Use is restricted to adults and adolescents aged 12 years and above; use below this age may not be established or is not permitted.

For specific populations, official use is governed by further constraints. Patients with severe renal impairment (severe kidney disease) may use the medicine but require an officially modified or reduced dosage limit compared to the standard dose. During pregnancy and lactation, use is typically restricted or advised against to avoid potential risk, often requiring weighing the clinical benefit against the known or potential risks to the fetus or infant. Patients are considered eligible for Vaster only if they do not have any listed contraindications and meet all specific population-based requirements.

What should I know about interactions with other medicines?

Vaster Interactions with other medicines and products

Vaster’s official interaction profile is defined by two primary mechanisms: the inhibition of the CYP3A4 enzyme and the blocking of the OATP1B1 hepatic uptake transporter. These pharmacokinetic interactions significantly increase the drug's systemic concentration.

Contraindicated Combinations

Co-administration is formally contraindicated with several classes of medicinal products due to the documented risk of greatly increased exposure. These substances, which include strong CYP3A4 inhibitors like certain macrolide antibiotics (e.g., Erythromycin), specific antifungal agents (e.g., Itraconazole), and HIV protease inhibitors, are strictly prohibited. Other prohibited agents include Ciclosporin, Danazol, and Gemfibrozil.

Other Documented Interactions

  • Pharmacodynamic Interactions: Interactions leading to an additive risk of muscle-related toxicity are documented with agents like Fenofibrate and high-dose Niacin (nicotinic acid ge 1 g/day).
  • Timing Rule: Co-administration with Bile Acid Sequestrants requires that Vaster be administered at least two hours before or four hours after the sequestrant to avoid physical binding and reduced absorption.
  • Food and Herbal Products: The consumption of large quantities of Grapefruit Juice is restricted due to its documented effect as a CYP3A4 inhibitor, which raises the drug’s plasma levels.

Regulatory documentation from authorities like the FDA and EMA defines this interaction structure based on established pharmacokinetic interference. This classification determines which combinations are officially prohibited and which require specific, label-based administration constraints.

Mechanism of Action

Direct Enzyme Blockade and Prodrug Activation

Vaster contains Simvastatin, an inactive molecule (prodrug) that undergoes metabolic conversion by liver enzymes to become its active beta-hydroxyacid form. This active form exerts competitive inhibition on HMG-CoA reductase, the enzyme regulating the body's internal synthesis of cholesterol via the Mevalonate pathway. This action immediately forces liver cells (hepatocytes) into a state of intracellular cholesterol depletion.

Homeostatic Response and LDL Receptor Upregulation

As a direct consequence of cholesterol depletion, the liver engages a critical feedback loop, increasing the number of Low-Density Lipoprotein Receptors (LDL-R) displayed on its cell surface. This increase in active LDL-R enhances the liver's ability to increase the clearance and catabolism of Low-Density Lipoprotein Cholesterol (LDL-C) particles from the circulating bloodstream. This regulated mechanism results in a reduction of systemic LDL-C concentrations.

Dosage and Administration Information

How to Use Vaster

This section outlines the general principles of how Simvastatin, the active ingredient in Vaster, is administered and dosed.


Administration and Timing

Vaster is supplied as an oral tablet and must be taken once daily. Standard administration specifies that the tablet should be administered in the evening to align with the body's natural cycle of cholesterol synthesis. The tablets may be ingested with or without food.

Official Dosing Regimens

Treatment is initiated alongside a standard cholesterol-lowering diet. For most adults, the usual starting dose is 10 mg or 20 mg once daily. The typical maintenance dosage range is between 5 mg and 40 mg per day.

Feature Guideline
Maximum General Daily Dose 40 mg
Titration Interval Not less than four weeks
Severe Renal Impairment Start 5 mg once daily
Pediatric (HeFH ge 10 years) Max 40 mg/day

Dosage adjustments, when required, must occur at minimum intervals of not less than four weeks to allow for assessment of the lipid-modifying effects.

Special Procedural Constraints

The 80 mg daily dose is subject to a specific restriction and is not recommended for initiating treatment in new patients. This dose is limited only to patients who have been stable on it for twelve months or longer without developing signs of muscle toxicity. In the event of a missed dose, the next dose should be taken as scheduled, and a double dose should not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vaster

Vaster, which contains the active substance Simvastatin, has been the subject of extensive research, primarily focused on research examining blood fat levels and the frequency of long-term cardiovascular events. The evidence base consists mainly of large-scale, long-term studies and comprehensive scientific reviews that examine measured outcomes over many years.


Evidence for Systemic Lipid Modification and Cardiovascular Health

Research into Simvastatin's use in the context of lipid modification has involved large numbers of participants over extended observation periods. Studies explored how the medicine affects key lipid biomarkers in the blood, such as Low-Density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol levels. The main research approach has utilized large, multi-year Randomized Controlled Trials (RCTs), where outcomes in patient groups were compared to control groups, and the findings from these trials were then consolidated into extensive scientific reviews and meta-analyses.

These large studies monitored major clinical events to understand long-term patterns. Research examined the frequency of serious heart and circulatory events, including non-fatal heart attacks, hospitalizations for unstable angina, and non-fatal strokes. Studies suggest that in the studied populations, measurements of LDL-C were observed to be different in the groups receiving the medicine compared to the control groups. Additionally, studies reported patterns related to the occurrence of these major heart events, and differences in event frequency were observed between the long-term Simvastatin study groups and the control groups over the typical 4 to 9-year follow-up periods.

Studies Focused on Primary and Secondary Prevention

Secondary prevention studies focused on individuals who had already experienced a heart attack or had established heart disease. Studies monitored these participants to see how the medicine was observed in relation to their risk of future events. Separately, primary prevention research focused on individuals at high risk for heart disease but who had not yet experienced a major heart event. Research describes patterns in both groups, suggesting that different baseline conditions may be associated with different measured outcomes.


Long-Term Evidence and Follow-up Duration

Studies explored the outcomes for participants over defined time intervals, with pivotal RCTs often lasting between four and nine years. Evidence derived from settings with varying symptom burdens includes additional observational follow-up studies that extended the monitored periods even longer. However, data for long-term outcomes are not fully established beyond the observation window of the longest RCTs, and often relies on data from observational settings where other life factors may influence the measured outcomes related to systemic or functional imbalance.

Key Studies & References

  1. NICE Guideline: Cardiovascular disease: risk assessment and reduction, including lipid modification

Frequently Asked Questions (FAQ)

Common questions about Vaster (FAQ)

Q: How long does it usually take to feel the effects of Vaster?

Vaster's effectiveness is a measurable biochemical effect, not a subjective feeling. Official information indicates that the reduction in cholesterol levels are typically assessed by a healthcare provider as early as four weeks after starting the medication or following a dosage change. This time frame allows the body to fully respond to the medicine.

Q: Is Vaster considered a 'new' drug, or has it been around for a while?

The active ingredient in Vaster is a well-established medicine that has been in clinical use for an extended period. This means it has a long history and has been the subject of extensive research and many updates to its official regulatory documentation over the years.

Q: Does Vaster have a generic version available yet?

Yes. According to official documentation, the active ingredient in Vaster (simvastatin) is widely available as a generic medication.

Q: Is Vaster safe for use in older adults (e.g., over 65)?

Regulatory documents indicate that advanced age, defined as 65 years and older, is a risk factor for certain muscular side effects like myopathy (muscle damage). For this reason, elderly patients are typically monitored for this increased risk.

Q: Can Vaster be taken by people with kidney problems?

Official product information notes that renal (kidney) impairment is a known risk factor for myopathy (muscle damage). Therefore, certain patients with severe kidney impairment may require a modified starting dosage.

Q: Why do official documents emphasize the importance of lab tests with Vaster?

Lab tests are a component of the official safety monitoring plan. Official documents require checking liver enzyme tests before starting therapy and periodically thereafter, as checking these markers helps assess liver function.

Q: Does Vaster carry any Black Box Warning from the FDA?

The FDA label does not include a formal Black Box Warning. However, there is a prominent warning detailing restrictions on the 80 mg daily dosage due to an elevated risk of severe muscle injury (rhabdomyolysis) when compared to lower doses.

Q: Is Vaster safe to use if I occasionally drink alcohol?

Regulatory documents note that consuming substantial quantities of alcohol can increase the risk of liver problems while taking this medication. Patients who regularly consume more than two alcoholic beverages per day are advised in the label to discuss this with their healthcare provider.

Q: Does taking Vaster affect my ability to drive or operate machinery?

The official prescribing information includes reports of adverse reactions such as dizziness, confusion, and cognitive impairment (like memory loss). While the risk is generally low, it is noted that these effects have the potential to affect the ability to drive or operate machinery.

Q: What kind of common over-the-counter medications might interact with Vaster?

The official label requires patients to report all medicines to their doctor, but specifically notes that high-dose niacin is known to interact. Additionally, consuming large quantities of grapefruit juice is listed as a restriction, as it affects how the drug is processed in the body.

Q: Does Vaster have an impact on fertility?

The drug's impact on fertility is addressed in the nonclinical toxicology data sections of the official prescribing information, which typically cover studies in animals.

Q: Is Vaster used to treat anything besides the main condition mentioned?

Yes. Beyond lowering elevated cholesterol, the official indications for Vaster also include reducing the risk of cardiovascular events, such as heart attack and stroke, in high-risk patients.

Q: Are there different forms of Vaster available (e.g., tablet, liquid)?

According to the official product information, the drug is available in the form of film-coated tablets and is also available as an oral suspension.

Q: Can Vaster be used by people who have diabetes?

Official regulatory warnings indicate that statin use may be associated with small increases in fasting blood sugar and glycosylated hemoglobin (HbA1c) levels. Patients with diabetes are advised in the label to discuss their current management plan with their healthcare provider.

Q: Is there a warning about using Vaster if someone is planning a surgery?

Official safety information indicates that patients experiencing major surgery or trauma are at an increased risk of muscle or kidney problems. Regulatory text suggests that temporary discontinuation may be advised for patients with acute, serious conditions.

Q: Does Vaster affect the results of common lab tests?

The official label notes that Vaster use has been associated with persistent elevations in hepatic (liver) transaminases. It has also been associated with increases in fasting blood sugar and HbA1c levels, which are markers monitored during lab work.

Q: Is Vaster safe for children and adolescents?

Official product information provides specific treatment guidelines for pediatric patients who are 10 years of age and older, but only when treating a specific hereditary condition (heterozygous familial hypercholesterolemia).

Q: Is it true that Vaster can affect sleep patterns?

The official prescribing information lists 'insomnia' (difficulty sleeping) among the adverse reactions reported through postmarketing surveillance. While reported, the incidence or frequency of these specific effects is not known.

How should Vaster be stored and disposed of?

Storage and Disposal of Vaster (Simvastatin)


Official Storage Requirements

Vaster tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product should be kept in its original container, tightly closed, and must be protected from excessive heat and moisture to maintain its quality. As a required safety measure, Vaster must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Vaster must be disposed of according to local requirements and should not be flushed down a toilet or sink, or thrown into household trash unless prepared according to specific guidelines. The best method for disposal is to use a community drug take-back program or an authorized mail-back service. If these options are unavailable, mix the tablets with an undesirable substance, seal them in a bag, and place them in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vaster found in:

A-Z Index: